NCT05421598: A reported trial by Sanofi
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05421598 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2022 |
| Completion date | Oct. 11, 2024 |
| Required reporting date | Oct. 11, 2027, midnight |
| Actual reporting date | March 9, 2026 |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |